8-K: Bausch + Lomb CEO Departs; Interim CEO Appointed, Guidance Raised

Bausch + Lomb Corporation announced the mutual departure of CEO Brent Saunders, appointing Thomas J. Appio as interim CEO, while also signaling an expected raise in full-year 2026 adjusted EBITDA guidance.

Summary

• Brent Saunders has departed as CEO and board member of Bausch + Lomb Corporation, effective October 12, 2026.
• Thomas J. Appio, Chairman of the Board and CEO of Bausch Health Companies Inc., has been appointed as the interim CEO.
• Saunders will receive a separation payment of $75.5 million and reimbursement of up to $50,000 in legal fees.
• All of Saunders' outstanding equity and incentive awards have been forfeited.
• The company expects to raise its full-year 2026 adjusted EBITDA guidance (excluding Acquired IPR&D).
• The press release announcing these changes was issued on October 12, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development due to the unexpected departure of the CEO and the significant payout, though the positive guidance update offers some counterbalance.

Positives

• The company expects to raise its full-year 2026 adjusted EBITDA guidance (excluding Acquired IPR&D), indicating strong business performance.
• Thomas J. Appio, the interim CEO, has deep knowledge of the business and a strong track record with Bausch Health.
• Brent Saunders' departure is stated to be without dispute or disagreement with the company.

Negatives

• The unexpected departure of the CEO, Brent Saunders, creates leadership uncertainty.
• A significant separation payment of $75.5 million is being made to the departing CEO.
• All of Brent Saunders' outstanding equity and incentive awards were forfeited, representing a loss of potential future compensation for him.

Risks

• Leadership transition risk associated with the departure of a CEO.
• Potential for market reaction to the CEO change and the substantial separation package.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects to raise its full-year 2026 guidance for adjusted EBITDA excluding Acquired IPR&D, citing strong third-quarter preliminary results and anticipated stronger performance for the remainder of the year. Additional details will be provided when third-quarter results are reported on October 28, 2026.

Management Comments

• "The opportunity to lead Bausch + Lomb is both a privilege and a responsibility that I embrace with great enthusiasm. Our company is built on the strength of our people, the quality of our portfolio and a relentless commitment to serving customers and patients around the world. With a strong foundation, we are well positioned to build on our momentum and deliver sustainable growth."
• "When I returned to Bausch + Lomb, I believed this company had tremendous potential. Today, it is stronger, more focused and better positioned for the future, with a clearer strategy, a more robust pipeline and significant opportunities ahead. The progress we've made reflects the talent, passion and commitment of colleagues across the organization, and I'm proud of everything we've accomplished together."

Industry Context

StockSavvy.ai notes that CEO transitions, especially when accompanied by significant financial packages, can introduce short-term volatility. However, the simultaneous positive guidance update suggests underlying business strength that may mitigate concerns about leadership changes in the eye health sector.

Management Changes

Stakeholder Impact

• Shareholders may experience short-term volatility due to the CEO transition, but the raised guidance is a positive indicator.
• Employees may face uncertainty regarding future leadership direction, though the interim CEO has strong ties to the organization.
• The substantial separation payment to the former CEO could be viewed critically by some stakeholders.

Next Steps

• Bausch + Lomb and Bausch Health will report third-quarter results on October 28, 2026, at which time additional details on the guidance update will be provided.
• Thomas J. Appio will serve as interim CEO while continuing as CEO of Bausch Health.
• Brent Saunders will provide transition assistance for 90 days following his departure date.

Key Dates

Recommendation

The departure of a CEO, even with an interim replacement and a significant payout, introduces uncertainty. While the raised guidance is positive, the market may wait for more clarity on the long-term leadership strategy and continued execution under the new interim leadership before making a decisive investment move.

Keywords

CEO departure, interim CEO, Bausch + Lomb, Bausch Health, guidance update, EBITDA, separation agreement, executive compensation